Pharmacologic class (EPC) · 3 drug pages

Immunoglobulin G: adverse event reports filed with FDA

8,877 reports list a drug in this class as a suspect or interacting product, 2004–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

8,877
reports across the class: 0% of all reports; 601
reports, 12 months to June 2026: 578 in the 12 months before; 97.1%
marked serious by the reporter: 57.4% across all reports; 3
drugs with a page: brand and generic names counted separately

Immunoglobulin G is a pharmacologic class (an FDA Established Pharmacologic Class) with 3 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 8,877 adverse event reports received by FDA, 0% of the database, from January 2004 to June 2026.

601 reports arrived in the 12 months to June 2026, close to the 578 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 97.1% of the class's reports are marked serious, 27.9% record death among the outcomes and 34.6% record hospitalisation, as reported.

Across the class the reactions recorded most often are pyrexia (9.8%), off label use (8%) and cytomegalovirus infection (5.5%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
ThymoglobulinAnti-thymocyte globulin (rabbit)	brand	6,283	308	97%	Pyrexia
Anti-thymocyte globulin (rabbit)	generic	1,982	260	98.8%	Off label use
AtgamEquine thymocyte immune globulin	brand	612	33	93.6%	Pyrexia

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Pyrexiafever9.8%874
Off label useused for a purpose or in a way not on the label8%714
Cytomegalovirus infection5.5%488
Drug ineffectivethe medicine did not work as expected5.4%478
Transplant rejection4.6%408
Sepsisa severe body-wide response to infection3.9%349
Febrile neutropeniafever with low white blood cells3.7%331
Pneumonialung infection3.6%318
Cytomegalovirus infection reactivation3.4%300
Acute graft versus host disease3.2%285
Acute kidney injurysudden loss of kidney function3.2%285
Pancytopenialow counts of all blood cells3.2%280
Post transplant lymphoproliferative disorder3.2%280
Thrombocytopenialow platelets3.1%274
Hypotensionlow blood pressure3%269
Epstein-Barr virus infection3%268
Diarrhoealoose or frequent stools2.9%261
Product use in unapproved indicationused for a purpose not on the label2.9%261
BK virus infection2.8%249
Acute graft versus host disease in skin2.7%236
Serum sickness2.7%236
Neutropenialow neutrophils, a type of white blood cell2.6%229
Cytomegalovirus viraemia2.5%219
Respiratory failurethe lungs could not supply enough oxygen2.3%205
Graft versus host disease2.3%202

Solid bar: share of all class reports. Hollow bar: the median share across the 3 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death27.9%2,474

Life-threatening11.4%1,013

Hospitalisation (initial or prolonged)34.6%3,075

Disability0.9%80

Congenital anomaly0%3

Other serious71.4%6,341

Not serious2.9%254

Patient age

Under 22.4%211

2 to 118.3%741

12 to 175%440

18 to 4420.3%1,801

45 to 6423.9%2,125

65 to 747.2%638

75 and over1.3%117

Age not given31.6%2,804

Who reported

Physician40%3,555

Pharmacist8.2%727

Other health professional45.4%4,033

Lawyer0%1

Consumer or non-health professional4.4%388

Not given1.9%173

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about Immunoglobulin G reports

Which drugs are in the Immunoglobulin G class on this site?

Thymoglobulin, Anti-thymocyte globulin (rabbit) and Atgam. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

8,877 reports through June 2026, 601 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

pyrexia (9.8%), off label use (8%), cytomegalovirus infection (5.5%), drug ineffective (5.4%) and transplant rejection (4.6%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.